Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952

Objective

Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive, reason why this procedure is typically not reimbursed.

Understanding the value of imaging of β-amyloid using positron emission tomography (PET) provides a unique opportunity to achieve 3 major goals: 1) improve the diagnostic workup of patients suspected of AD and their management; 2) stratify risk for AD and select homogenous groups for intervention; and 3) quantify treatment effects more accurately.

AMYPAD will address the above objectives by studying the onset, dynamics, and clinical relevance of brain β-amyloid
in the spectrum from normal aging to preclinical and prodromal AD. We will use β-amyloid-PET in an unprecedented large number of subjects (n=4000) from population studies, as well as memory clinics cohorts, with repeat imaging in up to 2000. In close collaboration with EPAD (www.ep-ad.org) the cohorts will be followed with to determine (surrogate) outcomes of cognitive decline and neurodegeneration.

Lead from VU-VUmc, the Consortium brings together a word-class team of highly synergistic partners from across Europe constituting a highly experienced and efficient β-amyloid imaging network including the most active European PET sites, to ensure effective tracer delivery, access to patients and expertise to technical knowledge and disease modelling.

AMYPAD will establish the true value of β-amyloid PET across the severity range of AD. Patients and clinicians will benefit from better and cost-effective diagnostic procedures and management, while academics and industry will benefit from better disease understanding, clear reimbursement strategy and more rationale and efficient clinical trial design.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• natural sciencesbiological sciencesneurobiology
• medical and health sciencesbasic medicineneurologydementiaalzheimer
• medical and health sciencesclinical medicineangiologyvascular diseases
• humanitieshistory and archaeologyhistory
• medical and health sciencesclinical medicineradiologynuclear medicine

Keywords

• amyloid
• Alzheimer's disease
• tracer delivery
• disease modelling

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic(s)

• IMI2-2015-05-04 - Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)

Call for proposal

(opens in new window) H2020-JTI-IMI2-2015-05-two-stage

Funding Scheme

Coordinator

Participants (16)